ProCE Banner Activity

D2EFT: Final Outcomes Analysis of Second-line DRV-/DTG-Based ART After First-line NNRTI Failure

Conference Coverage
Slideset

Phase IIIb/IV D2EFT trial found that both second-line DTG + DRV/RTV and DTG + TDF + (3TC or FTC) had superior efficacy to DRV/RTV + 2 NRTIs, greater weight gain.

Released: July 26, 2024

Expiration: July 25, 2025

Share

Faculty

Angela Davies

Angela Davies, MD

Assistant Professor of Medicine
UC Davis Cancer Center
Sacramento, CA

Provided by

Provided by Clinical Care Options, LLC in partnership with the International AIDS Society 

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc. and ViiV Healthcare.

Gilead Sciences, Inc.

ViiV Healthcare

Partners

IAS

ProCE Banner